Decoy Therapeutics Secures $3.5M PIPE and $17.5M Warrants to Fund Phase 1/2a Trials

1. PIPE Financing Structure

Decoy Therapeutics entered a PIPE with a healthcare institutional investor, raising $3.5M of common stock or pre-funded warrants at $5.91 per share.

2. Warrant Milestones and Potential Proceeds

The deal includes Series A, B and C warrants that can generate up to $3.5M, $7.0M and $7.0M respectively upon shareholder approval and key clinical milestones.

3. Use of Net Proceeds

Net proceeds are earmarked to advance the company’s lead D-MAV antiviral candidate into Phase 1 and Phase 2a clinical trials, targeting shared viral mechanisms.

4. Closing Conditions and Registration Rights

The closing, expected by June 29, 2026, is subject to customary conditions, and Decoy agreed to file resale registration rights within 15 days post-closing.

1. PIPE Financing Structure

2. Warrant Milestones and Potential Proceeds

3. Use of Net Proceeds

4. Closing Conditions and Registration Rights

Related News

Lam Research Shifts Focus to $140 B AI-Driven WFE Market, 26.5% Sales Jump

Carrier Global’s $1.5B Data Center Backlog Fuels 9.4% Stock Gain

FuboTV faces unresolved Disney bundling lawsuit after $50M YouTube TV settlement

Sources

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

SpaceX Gains FTC Clearance to Acquire $50M Mesh Optical, Sparks $4B Passive Buying

Moderna Leads S&P 500 Gains After Investor Day on Autoimmune Pipeline